

SUBB2M BREAST CANCER TEST RESULTS WEBINAR RECORDING

Melbourne, Australia, 3 July 2023: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**), is pleased to make available a recording of the online investor briefing held on 29 June 2023.

Through the briefing session, CEO Dr Leeearne Hinch, CSO Professor Greg Rice and CFO & Company Secretary, Mr Mark Edwards discussed INOVIQ's excellent SubB2M/CA15-3 breast cancer test data, released to ASX on 27 June 2023, followed by an investor Q&A session.

To view a copy of the recording, please visit the link below:

<https://www.inoviq.com/site/investors/presentations>.

A copy of the presentation that was delivered through the session was lodged with ASX on 29 June 2023.

INOVIQ thanks all those investors who were able to participate on the day.

- ENDS -

Authorised by the Company Secretary, Mark Edwards.

COMPANY CONTACTS

Dr Leeearne Hinch

Chief Executive Officer

E lhinch@inoviq.com

M +61 400 414 416

Dr Geoff Cumming

Non-Executive Chairman

E geoff.cumming@inoviq.com

M +61 417 203 021

Jane Lowe

IR Department

E jane.lowe@irdepartment.com.au

M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising next-generation exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO-NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. For more information on INOVIQ, see www.inoviq.com.

ABOUT SUBB2M PLATFORM

SubB2M is an engineered protein that preferentially binds to the pan-cancer biomarker Neu5Gc, found in multiple human cancers. INOVIQ is developing SubB2M blood tests for multiple uses, including monitoring breast and ovarian cancers, and for a general health panel.

SubB2M may enhance the performance of existing tumour marker tests by binding to multiple Neu5Gc sites on the biomarker that amplify the signal and improve sensitivity, and by increasing the cancer specificity to reduce false positives.